Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.,Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. ESMO 2018, abstract LBA50.
ADAPT-IT: aanpassen dosering nivo + ipi op basis van tussentijdse CT-scan bij gevorderd melanoom
jan 2022 | Dermato-oncologie, Immuuntherapie